Recent Licensing Changes The transfer of intellectual property assets from Direct Diagnostics to OralDNA Labs suggests potential opportunities to engage with OralDNA Labs for licensing, partnership, or acquisition discussions, particularly as they expand their diagnostic capabilities.

Product Focus on Salivary Diagnostics OralDNA Labs has demonstrated innovation in salivary diagnostic tests, including COVID-19 PCR tests, indicating a strong market niche that could benefit from advanced medical equipment, testing kits, and laboratory support solutions.

Market Expansion Potential The successful FDA emergency authorization and launch of COVID-19 tests point to an opportunity to support OralDNA Labs further expansion into infectious disease diagnostics and other health testing sectors.

Growth and Revenue Opportunity With revenue under 1 million dollars and a small team, there is significant potential for scalable sales of medical equipment, testing reagents, and laboratory automation tools to assist in increasing operational capacity.

Innovation in Pandemic Response OralDNA Labs’ rapid development and deployment of COVID-19 testing solutions highlight a readiness to adopt new diagnostic technologies, presenting a sales avenue for cutting-edge equipment and related services to enhance their testing capabilities.